Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

New Hope honored by FDA

This article was originally published in The Tan Sheet

Executive Summary

The agency bestows its Civilian Honor Award in the Leveraging/Collaboration category on New Hope Natural Media's standards program. The program, which launched in 1994, is part of an industry-wide effort to encourage self-regulation and cooperation, Boulder, Colo.-based New Hope said June 4. Fred Linder, the media firm's senior VP, said the honor is a significant achievement given that the agency "is not known for giving out gratuitous awards." Linder and his colleagues will receive the distinction at the June 26 Office of Regulatory Affairs Honor Awards ceremony in Washington

You may also be interested in...



TriSalus Thinks Its Drug/Device Strategy Can Optimize IO Regimens

The firm licensed the TLR9 agonist SD-101 from Dynavax to test with its pressure-enabled drug delivery technology in liver and pancreatic settings where immuno-oncology has shown moderate efficacy or less.

Advisory Committee For Biogen's Aducanumab Will Test US FDA's 'Substantial Evidence' Flexibility

Given inconsistent study results, robustness of the efficacy evidence is expected to be key focus of the 6 November meeting of the Peripheral and Central Nervous System Drugs Advisory Committee; review could put a December 2019 guidance on the ‘substantial evidence’ standard to the test and offer insight into the amount of flexibility the agency is willing to exercise for neurodegenerative diseases with high unmet need.

US FDA Connects Dots For Drug Manufacturers’ Responses To CRLs With Draft Guidance

CRLs FDA submits in response to ANDAs increased most years since FY 2015, though FY 2020 total likely will be lower than two previous years. A 2019 CRL interrupted GSK's plans to market first mouth spray nicotine replacement therapy in US.

Topics

UsernamePublicRestriction

Register

ID1128360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel